Manuka Töötajad 2024

Mis teeb Manuka?

Artemis Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of novel cancer drugs in the fields of immunooncology and cell therapy. The company was founded in California in 2014 and has been listed on the Nasdaq stock exchange since 2017. Artemis Therapeutics' business model is based on the belief that the future of cancer treatment lies in immunotherapies and gene therapies that stimulate the body's immune system to eliminate cancer cells. Therefore, the company has an extensive research and development department focused on identifying novel target molecules and therapeutics that can activate the body's immune system. Artemis Therapeutics collaborates closely with academic institutions and other research institutes to incorporate the latest scientific advancements into the development of new cancer drugs. The company also has strategic partnerships with other pharmaceutical companies to accelerate the development and commercialization of medications. Artemis Therapeutics currently has several product candidates in its pipeline. One of the most promising ones is ART201, a monoclonal antibody that binds to the protein PD-L1 expressed on many tumor cells, which disables the body's immune system against these cells. By blocking PD-L1, ART201 can enable the immune system to better recognize and fight cancer cells. The company has presented positive results from the Phase 1 study of ART201 and plans to commence further clinical trials soon. Another promising product candidate from Artemis Therapeutics is ART101, an autologous (derived from the patient's own cells) cell therapy in which the patient's T cells are genetically modified to directly attack specific cancer cells. Artemis Therapeutics has acquired exclusive rights to CRISPR-Cas9 gene editing technology from the University of California and plans to conduct additional clinical studies in the coming years to assess the safety and efficacy of ART101. In addition to ART201 and ART101, Artemis Therapeutics has also developed the ARTimmune platform technology, which allows for the rapid identification and testing of new antibodies against various types of cancer. This platform is based on a library of several million human antibodies collected from healthy donors. Artemis Therapeutics utilizes advanced technologies such as phage display and high-throughput sequencing to identify the most effective antibodies in the library. Artemis Therapeutics also has expertise in the manufacturing of biologics and has established its own production unit to enable the production of ART201 and other future products. The company has already entered into partnerships with other biologics manufacturers to outsource the production of ART201 and ART101 and increase efficiency. Artemis Therapeutics' products target a growing market for cancer drugs where immunotherapies and cell therapies are becoming increasingly important. The global market for cancer immunotherapies is expected to reach nearly $100 billion by 2024 as more patients are convinced of the benefits of these treatments. Artemis Therapeutics is well positioned to benefit from this growth as the company has a promising pipeline of product candidates and strong research expertise. Manuka ist eines der beliebtesten Unternehmen auf Eulerpool.com.